New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of ActionFN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently […]
3 Healthcare Stocks Insiders Are BuyingThe healthcare industry is looking forward to double-digit growth, and these stocks the insiders are buying have analyst support too.
3 Penny Stocks The Insiders Are BuyingThe insiders are buying these penny stocks with support from analysts and institutions. Could they be the next big winners?
Precigen’s Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T TherapyAcute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly.
PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON) on behalf of long-term stockholders following a class action complaint that was filed against Precigen on October 5, 2020 with a Class Period from May 10, 2017 to September 25, 2020. Our investigation concerns whether the board of directors of Precigen have breached their fiduciary duties to the company.
